Rahul Sharma, MD
Interventional Cardiology · Peoria, AZNPI 1063675288
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $117,435 of the $195,087 with a category attached, or 60.2%. Abbott accounts for 71.4% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2023 at $98,095 and has fallen 84.4% since, to $15,259 in 2025. Among interventional cardiology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 511 payments — averaging $381.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$139K
- Edwards Lifesciences$27K
- Medtronic$9K
- Cathworks, Inc.$5K
- Boston Scientific$4K
- Cardiva Medical, Inc.$4K
- plus $7K from 26 others
What the payments were for
- Consulting fees$117,43560%
- Speaking & faculty fees$8,3704%
- Travel & lodging$47,71424%
- Food & beverage$21,28611%
- Other$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 257 | $139,305 |
| Edwards Lifesciences | 62 | $26,744 |
| Medtronic(2 entities) | 42 | $8,848 |
| Cathworks, Inc. | 1 | $5,250 |
| Boston Scientific | 42 | $4,189 |
| Cardiva Medical, Inc. | 6 | $4,106 |
| Ancora Heart, Inc. | 8 | $2,325 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $1,160 |
| Abiomed | 22 | $1,116 |
| Philips North America LLC | 5 | $457 |
| Cardiovascular Systems Inc. | 3 | $350 |
| W. L. Gore & Associates, Inc. | 1 | $172 |
| Novartis | 6 | $129 |
| Biosense Webster, Inc. | 2 | $114 |
| Heartflow, Inc. | 1 | $108 |
| E.r. Squibb & Sons, L.L.C. | 5 | $93 |
| Sanofi | 1 | $70 |
| Jenavalve Technology, Inc. | 1 | $70 |
| Chiesi USA, Inc. | 3 | $57 |
| Baylis Medical Company Inc | 1 | $50 |
| AstraZeneca | 3 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Bayer | 2 | $40 |
| Pfizer | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| Atricure, Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $31 |
| Boehringer Ingelheim | 1 | $29 |
| Kestra Medical Technology Services, Inc. | 1 | $28 |
| Merck | 1 | $26 |
| Amgen | 1 | $19 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$124,104
- Edwards SAPIEN 3 Transcatheter Heart Valve$22,506
- COREVALVE EVOLUT R$6,000
- FFRangio$5,250
- NAVITOR$4,259
- SavvyWire$4,000
- AVVIGO Guidance System$1,737
- MitraClip$1,696
- CoreValve Evolut$1,318
- Watchman$891
- AMPLATZER$664
- LifeVest$609
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$587
- MitraClip System$573
- PORTICO$541
- SAPIEN 3 Ultra RESILIA$423
- AMPLATZER Occluders$416
- Impella$412
- Diamondback Coronary$350
- RESOLUTE ONYX$348
How this compares
$195,087 in reported general payments places this provider in the 95th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 446 | $415,709 |
| EntrestoSacubitril/Valsartan | 62 | $57,965 |
| XareltoRivaroxaban | 34 | $32,857 |
| BrilintaTicagrelor | 45 | $31,149 |
| Repatha SureclickEvolocumab | 23 | $25,728 |
| FarxigaDapagliflozin Propanediol | 27 | $20,724 |
| JardianceEmpagliflozin | 33 | $19,739 |
| NexletolBempedoic Acid | 11 | $4,301 |
| Ranolazine ErRanolazine | 34 | $3,425 |
| Metoprolol Succinate | 384 | $3,110 |
| Nifedipine ErNifedipine | 147 | $2,874 |
| ClopidogrelClopidogrel Bisulfate | 242 | $2,516 |
| Losartan Potassium | 248 | $2,302 |
| Carvedilol | 235 | $2,253 |
| Atorvastatin Calcium | 173 | $1,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $34 | $415,709446 claims |
| NovartisEntresto | $129 | $57,96562 claims |
| AstraZenecaBrilinta, Farxiga | $46 | $51,87472 claims |
| Johnson & JohnsonXarelto | $31 | $32,85734 claims |
| Boehringer IngelheimJardiance | $29 | $19,73933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Peoria
- Azimuddin KhawajaPeoria$199K
- Michael AmponsahPeoria$46K
- Wasiq ZaidiPeoria$33K
- Saifuldeen Al QaisiPeoria$27K
- Paul SorajjaPhoenix$1.1M
- Hursh NaikAvondale$781K
- Thomas WaggonerTucson$617K
- Timothy ByrnePhoenix$614K
- Haidar YassinPhoenix$434K
- Kapildeo LotunTucson$365K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.